FDA approval
07 Novembre 2007 - 8:01AM
UK Regulatory
RNS Number:1561H
Arthro Kinetics plc
07 November 2007
Press Release
Radio Frequency system receives 510(k) US FDA approval
WEDNESDAY, 7th November 2007 - Arthro Kinetics plc (AIM: AKI) ("Arthro
Kinetics"), the orthopedics company dedicated to regenerating joint mobility and
spinal disc function announces that its VESALIUS(R) radio frequency generator
and spinal probe system for soft tissue ablation has received 510(k) approval
from the US Food & Drugs Administration (FDA).
The Arthro Kinetics radio frequency generator and spinal probe system utilizes
the VESALIUS(R) molecular resonance technology allowing the spine surgeon to
easily, accurately and efficiently cut, ablate and seal soft tissue at lower
temperatures minimizing the potential for bleeding, scarring and other damage to
surrounding tissue.
Jason Loveridge, CEO of Arthro Kinetics commented:
"This is excellent news for Arthro Kinetics. Radio frequency technology is a
critical component of endoscopic surgery and this approval enhances
significantly the portfolio of instruments we can now make available to surgeons
in the US".
CONTACTS
Arthro Kinetics Plc Tel: +49 (0)711 305 110 70
Jason Loveridge, Chief Executive Officer
Doug Quinn, Chief Financial Officer
Nomura Code Securities Limited Tel: +44 (0)207 776 1200
Clare Terlouw
END
This information is provided by RNS
The company news service from the London Stock Exchange
END
REAUNUWRBWRARAA
Arthro Kinetics (LSE:AKI)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Arthro Kinetics (LSE:AKI)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Arthro Kinetics (London Stock Exchange): 0 recent articles
Plus d'articles sur Arthro Kinetics Plc